Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM functional rating scale

Author(s):
Badrising, U.A.; Henderson, R.; Reddel, S.; Corbett, A.; Liang, C.; Reardon, K.; Ghaoui, R.; Bulsara, M.; Brady, S.; Brusch, A.; Chan, D.; Coudert, J.D.; Fairchild, T.; Jain, G.; Kiernan, M.C.; Leonard, D.; Lloyd, T.; Schmidt, J.; Mcdermott, M.P.; Sanders, L.; Lowe, C.; Kooi, A.J. van der; Weihl, C.; Mohassel, P.; Simpson, M.; Carroll, A.; Cooper, I.; Beer, K.; Hiscock, K.; Walters, S.; Panicker, A.; Doverty, A.; Heim, A.J.; Heur-Neuman, M. van; Benveniste, O.; Dimachkie, M.M.; Needham, M.
Published
2025
Publication type
Article / Letter to editor

Abstract

Objective

Inclusion body myositis (IBM) is a complex inflammatory muscle disease in adults over 40, with histological features of autoinflammation, cell stress and autophagic abnormalities, and marked clinically by relentless progression with no effective disease-modifying therapy. Sirolimus (rapamycin) may help maintain function by inhibiting T effector cells, preserving T regulatory cells, inducing autophagy, and improving mitochondrial function. This international trial follows a phase II pilot study.

Methods This phase IIb/III double-blind, randomised, controlled trial (RCT) of sirolimus involves 140 IBM patients randomly assigned with equal allocation to sirolimus (2 mg) or matching placebo. This RCT aims to assess the efficacy of sirolimus compared to placebo in slowing or stabilising IBMprogression, as measured by the mean change in patient function using the IBM Functional Rating Scale (IBM-FRS) from Baseline to Week 84. Secondary outcomes will evaluate efficacy and safety to inform future clinical trial design. Results Ethical approval has been granted in Australia (St Vincent's Hospital Melbourne HREC-D 311/20) and the USA (University of Kansas Medical Center Human Research Protection Program FWA no. 00003411), with European approval pending. The protocol is version 3.0 (02-Dec-2022). Trial registration: ANZCTR: ACTRN12620001226998p, ClinicalTrials.gov: NCT04789070, UTN: U1111-1258-1354, and EU CT 2024-514575-17-00. Conclusion This phase IIb/III trial builds on prior findings to assess sirolimus's potential in slowing or halting IBM progression, preserving patient function and independence, and advancing IBM therapeutic strategies and trial design.

clinical trialsinclusion body myositisinternationalinvestigator-inititated
Date issued
2025-02-01
Language
English
Publisher
CLINICAL & EXPER RHEUMATOLOGY
Is part of
Clinical and Experimental Rheumatology (2025), Vol. 43, no. 2, p. 316-325
hdl
1887/4295355
doi
10.55563/clinexprheumatol/zvffa0